ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026
Anoctamin 2 deletion alters dopamine-related signaling and impairs inhibitory behavioral control in mice.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Anoctamin 2 (ANO2, TMEM16B) is a calcium-activated chloride channel best known for its role in sensory neurons, yet its expression in multiple brain regions associated with dopamine-related signaling, including the prefrontal cortex, striatum, substantia nigra, ventral tegmental area, and cerebellum, suggests broader functions in central neural circuits. However, the contribution of ANO2 to dopamine-related neural function and behavior remains undefined. To address this question, we generated ANO2-deficient mice using CRISPR-Cas9-mediated gene editing and examined their behavioral and neurochemical phenotypes. ANO2 knockout mice exhibited age-dependent hyperactivity, impaired inhibitory behavioral control, altered aversive/risk-related responses, and selective motor coordination deficits, while spatial learning and memory were preserved. Neurochemically, ANO2 deficiency resulted in reduced tyrosine hydroxylase expression and phosphorylation, decreased dopamine levels despite unchanged dopamine transporter expression, region- and subtype-dependent dopamine receptor alterations, and reduced downstream signaling markers across cortico-striatal and cerebellar circuits. These changes suggest impaired dopamine biosynthesis and altered dopamine-related signaling rather than broad disruption of dopaminergic neuronal identity. Together, these findings identify ANO2 as a potential modulator of dopamine-related signaling and inhibitory behavioral control, expanding current understanding of calcium-activated chloride channel function in neural circuits relevant to behavioral domains implicated in neuropsychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.